上海富雨生物科技有限公司
初級會員 | 第1年

18956075901

當(dāng)前位置:上海富雨生物科技有限公司>>細(xì)胞庫 / 細(xì)胞培養(yǎng)>>普通細(xì)胞>> SNU-398人肝癌細(xì)胞(附S

SNU-398人肝癌細(xì)胞(附S

參  考  價面議
具體成交價以合同協(xié)議為準(zhǔn)

產(chǎn)品型號

品       牌

廠商性質(zhì)生產(chǎn)商

所  在  地

更新時間:2025-02-11 18:16:16瀏覽次數(shù):25次

聯(lián)系我時,請告知來自 化工儀器網(wǎng)
同類優(yōu)質(zhì)產(chǎn)品更多>
人肝癌細(xì)胞SNU-398種屬人別稱SNU398; NCI- SNU- 39 8組織來源肝臟疾病肝細(xì)胞癌傳代比例/細(xì)胞消化1:2傳代 ,消化1-3分鐘,培養(yǎng)基配置RPMI1640 培養(yǎng)基: 10%胎牛血清

人肝癌細(xì)胞SNU-398

種屬
別稱SNU398; NCI- SNU- 39 8
組織來源肝臟
疾病肝細(xì)胞癌
傳代比例/細(xì)胞消化1:2傳代 ,消化1-3分鐘 ,
培養(yǎng)基配置RPMI1640 培養(yǎng)基: 10%胎牛血清 1%雙抗
簡介SNU-398 于 1990 年由 J.-G. Park 及其同事取自一名韓國患者的間變性肝細(xì)胞癌 ,該患者已通過脂質(zhì)體加 和-C 的組合進(jìn)行了經(jīng)導(dǎo)管動脈栓塞治療。既可以附著細(xì)胞也可以懸浮細(xì)胞。懸浮的細(xì)胞是可行 ,不應(yīng)丟 棄。通過溫和離心 (125 xg) 回收懸浮細(xì)胞 ,以與貼壁細(xì)胞群一起進(jìn)行繼代培養(yǎng)。
形態(tài)上皮細(xì)胞樣
生長特征懸浮貼壁生長
倍增時間每周 2 3
抗原表達(dá)Blood Type O; Rh +
STRAmelogenin: X,Y CSF1PO: 13 D13S317: 11 D16S539: 10, 14 D5S818: 12 D7S820: 10, 11 THO1: 7,9 TPOX:11 vWA: 17, 18
保藏機(jī)構(gòu)ATCC; CRL- 2233

Background: Hospitals face mounting pressure to reduce unplanned utilization amid rising healthcare demands from an aging population. The Case management for At-Risk patients in the Emergency Department (CARED) program is among the first ED transitional care strategies to focus on both frail older adults and Emergency Department (ED) re-attenders to reduce acute hospital utilization. This study aims to evaluate the effectiveness of the CARED program in reducing hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge.

Methods: A retrospective, propensity-matched study was conducted from April 2022 to July 2023 in the ED of Ng Teng Fong General Hospital in Singapore. The CARED program identifies and enrols at-risk patients i.e., frail older adults and patients who re-attend the ED within 30 days of hospital discharge, for a geriatric assessment. This is followed by multidisciplinary team care, discharge planning and right siting of care from the ED to community-based services by ED case managers. The primary outcomes were hospital (re)admissions and ED re-attendances within 30- and 60-days post-discharge. Secondary outcomes were cost avoidance and bed occupancy days from reduced acute hospital usage.



untreated host, most aeTSAs are undetected by the immune system. We present evidence suggesting that vaccines inducing direct aeTSA presentation by DCs may represent an attractive strategy for cancer treatment.Checkpoint inhibitors (eg, programmed cell death protein 1 [PD-1], programmed cell death ligand 1 [PD-L1], cytotoxic T-lymphocyte associated protein 4 [CTLA-4] antibodies) are changing how we understand cancer and provide a means to develop modern

會員登錄

×

請輸入賬號

請輸入密碼

=

請輸驗證碼

收藏該商鋪

X
該信息已收藏!
標(biāo)簽:
保存成功

(空格分隔,最多3個,單個標(biāo)簽最多10個字符)

常用:

提示

X
您的留言已提交成功!我們將在第一時間回復(fù)您~
撥打電話
在線留言